FindTrial
Sign In

miR-145 in patients of Systemic Lupus Erythematosus

Role of miR-145 in Systemic Lupus erythematosus - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/06/068573
Enrollment
60
Registered
2024-06-07
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M321- Systemic lupus erythematosus withorgan or system involvement

Interventions

Intervention1: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

Chhattisgarh Council of Science and Technology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of SLE fulfilling EULAR/ACR criteria

Exclusion criteria

Exclusion criteria: Pregnant and lactating females Malignancy Patients with chronic hepatitis B, C or HIV Any active infection diabetes mellitus Overlapping autoimmune disease

Design outcomes

Primary

MeasureTime frame
1. Study the expression of plasma miR-145 level in SLE patients and controls. 2. Transfection of miR-145 in human renal epithelial cells and study its effect on alpha SMA and E-cadherin moleculesTimepoint: Baseline—

Secondary

MeasureTime frame
To study the correlation of miR-145 expression with SLE clinical severityTimepoint: Baseline—

Countries

India

Contacts

Public ContactDr Rachita Nanda

AIIMS Raipur

dr.rachitananda@aiimsraipur.edu.in8518881763

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026